Monoclonal antibodies for the treatment of cancer: A brief overview
DOI:
https://doi.org/10.33064/iycuaa2024924653Keywords:
monoclonal antibodies, hybridoma, cancer, antigens, antibodies, adverse effectsAbstract
Immunotherapy is a powerful tool in the treatment of chronic-degenerative diseases such as cancer, is targeted at the immune system to trigger strong memory immune response and are key in treatment against tumor cells through long-term anti-tumor immune response and cell death by binding specific to target antigens and the activation of various mechanisms, with low toxicity and minimal described adverse events. The FDA has approved 31 monoclonal antibodies, but side effects still occur. Therefore, our objective was to present a bibliographic review in MEDLINE and academic Google on the advances, uses, mechanisms of action and unwanted effects of monoclonal antibodies in the treatment of cancer.
Downloads
Metrics
References
• American Cancer Society. (2019). Anticuerpos monoclonales y sus efectos secundarios. https://www.cancer.org/es/cancer/como-sobrellevar-el-cancer/tipos-de-tratamiento/inmunoterapia/anticuerpos-monoclonales.html.
• Arias, G.A., & Modjtahedi, H. (2021). Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. Cancers, 13(8), 1781. https://doi.org/10.3390/cancers13081781.
• Bermúdez, K., Hidalgo, G., Mora, R., Rodríguez, K., Ysmael-Acle, B., & Mora R.J.J. (2019). Anticuerpos monoclonales biespecíficos: desarrollo, producción y uso como terapia anticancerígena. Revista Médica de la Universidad de Costa Rica, 13 (2): 11-29. DOI: 10.15517/rmucr.v13i1.37573.
• Bayer, V. (2019). An overview of monoclonal antibodies. Seminars in Oncology Nursing, 35 (5): 150927. https://doi.org/10.1016/j.soncn.2019.08.006.
• Espinosa, M.E., Góngora, K.B., & Alfonso, L. (2019). Aplicaciones de los anticuerpos monoclonales en la medicina del siglo XXI. Revista Electrónica Dr. Zoilo E. Marinello Vidaurreta, 44 (1): 1-8. https://revzoilomarinello.sld.cu/index.php/zmv/article/view/1507/pdf_540.
• García, A. ( 2011). Anticuerpos monoclonales. Aspectos básicos. Neurología. 26(5):301-306. DOI: 10.1016/j.nrl.2010.10.005
• Instituto Nacional de Cáncer (INC) (2019). Anticuerpos monoclonales. https://www.cancer.gov/espanol/cancer/tratamiento/tipos/inmunoterapia/anticuerpos-monoclonales.
• Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., .... & Pan, L. (2021). Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduction and Targeted Therapy, 7 (39):1-28. https://doi.org/10.1038/s41392-021-00868-x.
• Bethesda, (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–.Monoclonal Antibodies. In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. 2023 Feb 28.
• Melgarejo, G., Pérez, S.M., Medina, E., & Velasco, M.A. (2019). Anticuerpos conjugados a fármacos: la nueva generación de terapias biotecnológicas contra el cáncer. Gaceta Médica De Mexico, 156 (3). https://doi.org/10.24875/gmm.20005572.
• National Institutes of Health (NIH). Monoclonal Antibodies (2019). https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies.
• Ni, H., Cao, L., Wu, Z., Wang, L., Zhou, S., Guo, X., ... & Liu, J. (2022). Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody. Cancer Immunology, Immunotherapy, 71(2), 353–363. https://doi.org/10.1007/s00262-021-02989-2.
• Si, Y., Melkonian, A.L., Curry, K.C., Xu, Y., Tidwell, M., ... & Liu. X. (2020). Monoclonal antibody-based cancer therapies. Chinese Journal of Chemical Engineering, 30: 301-307. https://doi.org/10.1016/j.cjche.2020.11.009
• Singh, S., Kumar, N.K., Dwiwedi, P., Charan, J., Kaur, R., Sidhu, P., & Chugh, V.K. (2018). Monoclonal Antibodies: A Review. Curr Clin Pharmacol.13 (2):85-99. https://doi.org/10.2174/1574884712666170809124728.
• Tsao, L.C., Force, J., & Hartman, Z.C. (2021). Mechanisms of Therapeutic Antitumor Monoclonal Antibodies. Cancer Research, 81 (18), 4641-4651. https://doi.org/10.1158/0008-5472.can-21-1109.
• Verina, D., Fowler, A., Louw, K., Barnes, Y., & Vickroy, A. (2022). CD38 Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma. The Journal for Nurse Practitioners, (18), 693- 698. https://doi.org/10.1016/j.nurpra.2022.05.001
• Wellstein, A., & Atkins, M.B. (2022). Anticuerpos, linfocitos t car y proteínas para tratar el cáncer. Brunton L.L., & Knollman B.C.(Eds.), Goodman & Gilman: Las bases farmacológicas de la terapéutica, 14e. McGraw Hill.
• Zahavi, D., & Weiner, L. (2020). Monoclonal Antibodies in Cancer Therapy. Antibodies, 9 (34): 1-20. https://doi.org/10.3390/antib9030034.
• Zinn S., Vazquez-Lombardi R., Zimmermann C., Sapra P. Jermutus L., & Christ D. (2023). Advances in antibody-based therapy in oncology. Nature Cancer, 4(2):165-180. https://doi.org/10.1038/s43018-023-00516-z.
Downloads
Published
License
Copyright (c) 2024 Dharana Gutiérrez-Chávez, María Fernanda Gómez-Valencia , Itzel Viridiana Reyes-Pérez , María Evarista Arellano-García, Olivia Torres-Bugarín
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Las obras publicadas en versión electrónica de la revista están bajo la licencia Creative Commons Atribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0)
